Lyell Immunopharma, Inc. — Director's Dealing 2025

Nov 11, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-10-31

Reporting Person: Bulis Veronica Sanchez (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9452	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$42.60	2033-02-23	Common Stock (1674)		Direct
Option (right to buy)	$37.40	2032-03-15	Common Stock (624)		Direct
Option (right to buy)	$37.40	2031-09-09	Common Stock (3000)		Direct

Footnotes

F1: Includes restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting and will be settled in common stock subject to vesting as follows: (1) 38 shares that will vest quarterly over the six-month period following August 9, 2025; (2) 312 shares that will vest quarterly over the eighteen-month period following August 9, 2025; (3) 2,516 shares that vest quarterly over the thirty month period following August 9, 2025 and (4) 3,937 shares that vest quarterly over the forty-two-month period following August 9, 2025; in each case, subject to the reporting person providing service through the applicable vesting date.

F2: 12.5% of the option shares vested on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.

F3: 12.5% of the option shares vested on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.

F4: Fully vested.